Integra LifeSciences Holdings Corp Stock News

Integra LifeSciences Holdings Corporation (IART) CEO Jan De Witte on Q4 2021 Results - Earnings Call Transcript

PRINCETON, N.J. (AP) _ Integra LifeSciences Holdings Corp. (IART) on Wednesday reported fourth-quarter net income of $45.4 million. The Princeton, New Jersey-based company said it had net income of 53 cents per share. Earnings, adjusted for non-recurring costs, came to 84 cents per

Integra Lifesciences (NASDAQ: IART ) reported its Q4 earnings results on Wednesday, February 23, 2022 at 06:00 AM. Here''s what investors need to know about the announcement. Earnings Integra Lifesciences beat estimated earnings by 1.2%, reporting an EPS of $0.84 versus Full story available on Benzinga.com

Integra LifeSciences Holdings press release (IART): Q4 Non-GAAP EPS of $0.84 in-line.Revenue of $405.5M (+4.3% Y/Y) beats by $2.09M.For the first quarter 2022, the Company

Integra (IART) delivered earnings and revenue surprises of 1.20% and 0.49%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Integra LifeSciences Holdings (NASDAQ:IART) is scheduled to announce Q4 earnings results on Wednesday, February 23rd, before market open.The consensus EPS Estimate is $0.84 (flat Y/Y)

Integra LifeSciences Holdings (IART) enters into $125M accelerated share repurchase agreement at par value $0.01/share.The repurchase transactions are expected to be completed in the

Integra's (IART) preliminary revenue results and recent plans to implement a $125-million share repurchase instill investor optimism.

The "Veterinary Orthopedics Market Research Report by Product Type, by Application, by End-use, by Region - Global Forecast to 2027 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com''s offering. The Global Veterinary Orthopedics Market size was estimated at USD 492.46 million in 2020, is expected to reach USD 536.39 million in 2021, and is projected to grow at a CAGR of 9.28% to reach USD 916.90 million by 2027. Competitive Strategic Window: The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period. FPNV Positioning Matrix: The FPNV Positioning Matrix evaluates and categorizes the vendors in the Veterinary Orthopedics Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive

Integra LifeSciences Holdings Corp (NASDAQ: IART ) expects Q4 FY21 sales of $404 million - $406 million , representing an increase of approximately 4% Y/Y on a reported basis and 8% on an organic basis. Interim Q4 sales beat the consensus of $403.9 million. In its

Integra LifeSciences Holdings Corp (NASDAQ: IART) expects Q4 FY21 sales of $404 million - $406 million, representing an increase of approximately 4% Y/Y on a reported basis and 8% on an organic basi

Integra LifeSciences Holdings (IART) releases its preliminary revenue estimate for fourth quarter that lands slightly above the market expectation. The medical technology on Tuesday

Integra LifeSciences (IART) has reported preliminary financial results, expecting Q421 revenue in the range of $404M to $406M (up around 4% Y/Y on a reported basis and +8% on an

Fourth quarter 2021 revenue is expected to be in a range of $404 million to $406 million, representing an increase of approximately 4% on a reported basis and an increase of approximately 8% on an organic basis compared to the prior year. Full-year 2021 revenue is expected to be in a range of $1,541 million to $1,543 million, representing an increase of approximately 12% on a reported basis and an increase of approximately 14% on an organic basis compared to the prior year. The company is planning a $125 million share repurchase as a part of a previous approval by the Board of Directors, with an authorization of up to $225 million. PRINCETON, N.J., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART ), a leading global medical technology company, announced today certain unaudited preliminary fourth quarter and full-year 2021 revenue results. Preliminary Fourth Quarter and Full-Year 2021 Revenue Results Fourth quarter 2021 revenue is expected to be in a range of $404 million to $406 million, representing an increase of approximately 4% on a reported basis and an increase of approximately 8% on an organic basis compared to the prior year.